Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ACP-196 in Healthy Subjects
NCT04901923Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Mar 2014
- Primary completion
- May 2014
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) (7 cohorts), sponsored by Acerta Pharma. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration at Day 9, Area Under the Concentration-time Curve From Time 0 to Infinity at Day 9 and 4 more. Started Mar 2014; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04901923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901923.